Clinical trial
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive…
NCT02097121 · Allergan, Industry · Terminated
Key facts
| NCT number | NCT02097121 |
|---|---|
| Title | OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) |
| Official title | BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age |
| Lead sponsor | Allergan, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urinary Incontinence, Urinary Bladder, Overactive |
| Intervention type | Biological |
| Interventions | BOTOX® |
| Enrollment | 56 |
| Start date | May 23, 2014 |
| Primary completion | Feb 10, 2022 |
| Completion | Feb 10, 2022 |
| First posted | Mar 26, 2014 |
| Last update posted | Dec 28, 2022 |
| Countries | Australia, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, South Africa, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: